Platforms - Creative Biolabs

Bispecific Antibody (BsAb) Developability Assessment
Our Developability Assessment Platform provides comprehensive evaluation of bispecific antibody candidates early in the development process. This sophisticated system integrates in silico tools, protein structure expertise, and experimental protocols to identify potential challenges related to stability, solubility, and manufacturability. By assessing critical parameters including expression levels, physicochemical properties, chemical modifications, and in vivo characteristics, we minimize the risk of late-stage failures and accelerate the selection of optimal bispecific antibody candidates. This platform ensures your molecules possess the necessary drug-like properties for successful development and clinical progression.

Bispecific Antibody (BsAb) Sequencing
Our Sequencing Platform utilizes state-of-the-art database-assisted shotgun sequencing (DASS) technology built on next-generation sequencing infrastructure. Featuring high-field Orbitrap Elite hybrid mass spectrometry with exceptional resolution and accuracy, we deliver precise sequence determination for complex bispecific antibodies. Our platform guarantees comprehensive coverage of V(D)J regions and accurate CDR3 sequencing, supporting antibodies from multiple species and formats. This technology is essential for antibody validation, quality control, and intellectual property protection throughout the development process.

Bispecific Antibody Mimetics Development
Our Antibody Mimetic Platform leverages alternative scaffold proteins to create bispecific molecules with enhanced properties. This innovative approach utilizes non-immunoglobulin scaffolds that offer advantages in stability, size, and manufacturability while maintaining high affinity and specificity. We engineer various scaffold formats including single-domain proteins and multimeric constructs, enabling unique therapeutic mechanisms such as extended half-life and enhanced receptor blocking. This platform expands the possibilities for bispecific molecule design beyond traditional antibody formats.